Iconovo has moved into new labs and offices at Medicon Village. We have now doubled our space and have several specialized labs and equipment for dry powder formulation development and analytical work. We have also invested in climate cabinets to be able to perform stability studies.
Iconovo has a new granted patent
The Swedish Patent and Registration Office, PRV, has granted Iconovo's first ICOone patent. This is a key milestone showing that Iconovo's inhalers are novel and inventive. More patent applications regarding ICOres, ICOcap and ICOone will soon enter the PCT phase.
Dr Mikael Arinder joins Iconovo
Dr Mikael Arinder is Iconovo's new Vice President Operations. Mikael has a PhD. in organic chemistry and has long experience from the pharmaceutical industry and particularly from the respiratory area. Mikael was with AstraZeneca for 14 years and had many senior roles. He now joins us from McNeal where he was Associate Director of Analytical Development. Mikael will be responsible for Iconovo's customer projects.
Iconovo enters into licensing and product development with Amneal Pharmaceuticals
Iconovo has signed an agreement for a licensing deal and a product development project with Amneal Pharmaceuticals that produce and market generic drug products. The agreement involves an adaptation of Iconovo’s unique inhaler, ICOres™ as well as a development of a powder formulation to treat asthma and COPD. Iconovo will receive an up-front payment and milestone payments in the mid-single digit Euro millions range during development through regulatory approvals and royalties after commercial launch.
Iconovo receives grant from Sweden’s innovation agency
Iconovo has received a 350 000 USD grant from Sweden’s innovation agency Vinnova. The development project includes optimization of ICOone and adaptation for high-volume low-cost commercial manufacturing. ICOone is primary intended for inhaled vaccines but is also suitable for biomolecules and high cost drugs.
Iconovo to develop novel inhaled drug formulations together with University of Copenhagen
Iconovo has signed a development agreememt with Copenhagen University. Iconovo's unit-dose inhaler ICOone will be used in two PhD projects investigating novel drug formulations at Faculty of Health and Medical Sciences. ICOone is the perfect test device when developing either traditional drug formulations or novel engineered drug formulations.
ICOone wins innovation award
Iconovo won the Lund University Innovation Award. The winning project was "ICOone for inhaled vaccines". Vaccines are currently administered as injections, which in addition to the associated discomfort also presents a variety of other challenges. One major problem with needles is that they are dangerous to use and can spread infections if not properly handled after use. Another concern is that vaccines for injection must be refrigerated, which is costly and large quantities of vaccine may need to be discarded as a result. Iconovo’s technology solves such problems since the shelf life of inhaled dry powder at room temperature is several months and the inhaler is completely harmless during and after use.
ICOone in the finals to win innovation award
Iconovo is in the finals to win the Lund University Innovation Award. ICOone for inhaled vaccine was presented to the jury and judged on the level of innovation and commercial potential. Iconovo was selected top three with a chance to win the innovation award. First prize is 150000SEK and the two second prizes are 50000SEK. The winner will be announced at the 6th of November at a ceremony in Lund. The award is sponsored by PWC.
Injection molded ICOcap
The development of Iconovo's proprietary capsule based inhaler, ICOcap has reached an important milestone. The first mold tools have been manufactured and the first injection molded devices have been delivered. The mold tools are single cavity technical tools and will be used to produce devices for mechanical verification and performance testing together with clients.
Pulmonary Drug Delivery: Advances and Challenges
Orest Lastow is the co-author of a recently published book titled "Pulmonary Drug Delivery: Advances and Challenges". The book addresses problems associated with inhalation formulation design, including the interaction between the active pharmaceutical ingredient(s) (APIs), excipients and devices. Orest has written chapter 16 "Future Patient Requirements on Inhalation Devices: The Balance between Patient, Commercial, Regulatory and Technical Requirements", see table of contents.
The book is available directly from Wiley and from e.g. Amazon.com.
Connectivity in Medical Technology - Electronics in ICOone and ICOres
Iconovo CEO Dr Orest Lastow will speaking at Connectivity in Medical Tecknology organized by Management Forum in London 24-25 June. The speach is titled "The use of electronics to improve and monitor compliance". The speach will focus on the use of electronics in ICOone and ICOres as a mean to improve adherence and compliance by offering an improved user interface. The main topics of the talk are:
- Opportunities to improve compliance with better user interface
- The benefits of electronics in clinical trials
- Risks and undesired effects of compliance monitoring
Management Forum- Dry Powder Inhalalers
Iconovo CEO Dr Orest Lastow has been invited to give a presentation about the Iconovo inhalation devices at the Dry Powder Inhalar conference organized by Management Forum in London 10-11 June. The speach is titled "Iconovo Device Range" and will include the following topics.
- Key strategies when developing a versatile and comprehensive device platform
- How to develop novel devices that are equivalent to devices on the market
- BE challenges on devices for generic products
- Key features, results and lessons learned
New Updates in Drug Formulation and Bioavailability
Iconovo´s CEO Dr Orest Lastow will be moderating the New Updates in Drug Formulation and Bioavailability conference in Copenhagen 7 April. Formulation and bioavailability are critical steps in the development process of new effective drugs. Failure in clinical trials can often be explained by poor formulation and bioavailability properties of the drug. The conference is open for registration and expects to attract 100 delegates and 12 exhibitors.
Computational Fluid Dynamics, CFD
Iconovo has invested in the Autodesk Simulation CFD software. Iconovo CEO Dr Orest Lastow was previously head of the AstraZeneca CFD group and has long experience from the optimization of the aerodynamics in inhalation devices. More details about the software at http://www.autodesk.com/products/simulation-cfd/overview
New lab facilities
Iconovo has moved into new lab facilities. The new facilities will allow us to perform verification and performance testing of the devices in development. Iconovo has access to carrier based formulations and micronized spheronized formulation for testing.
Published paper in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Iconovo CEO Dr Orest Lastow has published a paper in Journal of Aerosol Medicine and Pulmonary Drug Delivery. The paper is titled “Orally Inhaled Drug Performance Testing for Product Development, Registration, and Quality Control” and describes different approaches to testing inhalation products during development. The paper is available at http://online.liebertpub.com/doi/full/10.1089/jamp.2014.114
Great interest at DDL
Iconovo was a silver sponsor at DDL 25 in Edinburg, http://www.ddl-conference.org.uk DDL is the internationally most important inhalation conference held annually in Edinburg. Over 600 delegates representing all major pharmaceutical companies and generic
companies. We had an exposition showing our device line-up. There was a great interest
in our devices and we met many new potential customers.
Iconovo has raised 1 million USD for inhalation device development
Iconovo has raised 1 million USD in venture capital funding to develop inhalation devices. Lennart Holm has also increased his equity share in the company. Lennart Holm is the chairman of the board of the Swedish company BillerudKorsnäs AB and also of Nexam AB and Vigmed AB. Iconovo is based at Medicon Village in Lund and is founded, among others, by ex AstraZeneca employees.
Iconovo is developing proprietary dry powder inhaler devices for licensing to pharmaceutical companies. The primary market is generic companies planning to enter the inhalation business but lacking access to devices. The devices are primary intended for asthma and COPD but also for vaccines and biomolecules. “This funding will take us to a level where we have injection molded prototypes with verified performance”, says Orest Lastow, CEO of Iconovo.
Silver sponsor of MVIS
ICONOVO is a silver sponsor of MVIS (Medicon Valley Inhalation Symposium) 15 October in Lund. We will exhibit our prototypes showing our recent development advances.
Iconovo represented at MEDTEC 2014
Orest Lastow was an invited speaker at MEDTEC Europe 2014 in Stuttgart. He talked about the use of quality by design, QbD, in the development of inhalation products. The talk included a general introduction to the development of inhalation products and a step by step explanation of how to use QbD in the development. The benefits and risks of QbD were also discussed.
Iconovo receives support from the VINNOVA programme VINN NU 2013!
We are really proud to announce that Iconovo has received a grant from VINNOVA. The price ceremony was held at VINNOVAs headquarters in Stockholm on the 21 of November. "Of 209 applicants only 20 companies received a grant" says a more than happy Mats Johansson, chairman of the board, and continues "and now we have another 300 000 reasons to be happy!"